Form 4: Day One Biopharmaceuticals CEO Jeremy Bender Reports Stock Transactions
SEC Form 4
CEO Jeremy Bender reports acquisition and disposal of Day One Biopharmaceuticals stock, including transactions related to tax liability and RSU settlements.
Summary
- Jeremy Bender, CEO of Day One Biopharmaceuticals, reported changes in beneficial ownership of the company's stock.
- On August 15, 2024, Bender acquired shares through the settlement of Restricted Stock Units (RSUs).
- Specifically, 3,562 shares, 4,750 shares, and 11,687 shares were acquired through RSU settlements.
- On August 16, 2024, Bender disposed of 10,681 shares at a price of $13.9991 per share to cover tax liabilities related to the RSU settlements.
- Following these transactions, Bender directly owns 98,932 shares of common stock.
- Bender also indirectly owns shares through several trusts, including The Jeremy Bender 2022 Grantor Retained Annuity Trust (162,762 shares), The Jeremy Bender 2023 Grantor Retained Annuity Trust (219,406 shares), The Melissa Bender 2022 Grantor Retained Annuity Trust (222,030 shares), The Melissa Bender 2023 Grantor Retained Annuity Trust (197,614 shares), and the Bender Revocable Trust (807,026 shares).
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's future.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors monitor these filings for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives.
- The transactions are typical for executives receiving stock-based compensation and managing their tax liabilities.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the sale was primarily for tax purposes.
- Employees holding RSUs may be interested in the vesting schedule and tax implications.
Key Dates
| Date | Description |
|---|---|
| January 18, 2017 | Date of the Bender Revocable Trust. |
| March 29, 2022 | Date of The Jeremy Bender 2022 Grantor Retained Annuity Trust and The Melissa Bender 2022 Grantor Retained Annuity Trust. |
| June 27, 2023 | Date of The Jeremy Bender 2023 Grantor Retained Annuity Trust and The Melissa Bender 2023 Grantor Retained Annuity Trust. |
| August 15, 2024 | Date of RSU settlement and acquisition of shares. |
| August 16, 2024 | Date of sale of shares to cover tax liability. |
| August 19, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.